Polarean Imaging PLC Exercise of Warrants (4114I)
07 August 2023 - 8:00AM
UK Regulatory
TIDMPOLX
RNS Number : 4114I
Polarean Imaging PLC
07 August 2023
Polarean Imaging Plc
("Polarean" or the "Company")
Exercise of Warrants, PDMR Dealing, Issue of Equity and Total
Voting Rights
Polarean Imaging plc (AIM: POLX), a commercial-stage medical
device leader in advanced MRI scanning of the lungs, announces that
it has received notification from Mr. Kenneth West, Chairman of the
Company, to exercise 1,948,262 warrants over ordinary shares in the
Company (the "Warrants"). These warrants representing 1,948,262
ordinary shares of GBP0.00037 each in the capital of the Company
("Ordinary Shares") have an exercise price of US$0.007485 per
Ordinary Share. Mr. West has indicated that he does not plan to
sell any of these shares at the present time.
After the exercise of the Warrants, Mr. Kenneth West holds a
total of 3,276,678 Ordinary Shares and options for 2,263,218
Ordinary Shares.
The 1,948,262 new Ordinary Shares have been issued and admitted
to trading on AIM pursuant to the Block Listing announced by the
Company on 23 July 2021. The new Ordinary Shares will rank pari
passu with the existing Ordinary Shares.
Notifications have been made in accordance with the requirements
of the UK Market Abuse Regulation in respect of the PDMR and
further details can be found by following this link:
https://www.polarean-ir.com/content/investors/shareholder-information
Total voting rights
Following the issue and allotment of the Ordinary Shares, the
Company's issued share capital comprises 215,848,593 Ordinary
Shares. The Company does not hold any Ordinary Shares in treasury.
Therefore, the total number of voting rights in the Company is
215,848,593.
The figure of 215,848,593 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change of their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Christopher von Jako, Chief Executive Via Walbrook PR
Officer
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw
(Healthcare
Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical imaging
technology companies operating in the high-resolution medical
imaging space. Polarean aspires to revolutionise pulmonary medicine
by bringing the power and safety of MRI to the respiratory
healthcare community in need of new solutions to evaluate lung
ventilation, diagnose disease, characterise disease progression,
and monitor response to treatment. By researching, developing, and
commercialising novel imaging solutions with a non-invasive and
radiation-free functional imaging platform. Polarean's vision is to
help address the global unmet medical needs of more than 500
million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarisation
science and has successfully developed the first and only
hyperpolarised MRI contrast agent to be approved in the United
States. The company also commercialises systems (such as the HPX
hyperpolarisation system), accessories (such as Xe-specific chest
coils and phantoms) and FDA-cleared post-processing software (to
support ventilation defect analysis), to support fully integrated
modern respiratory imaging operations.
PLC-RNS-2317
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEUSUVROOUWRAR
(END) Dow Jones Newswires
August 07, 2023 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024